Peer Reviewed Publications
Hitchcock T. A CDMO’s Perspective on AAV Vector Production. GEN. October 2020.
M Otmani. Special Report: COVID-19. Facing an Ongoing Pandemic. Nordic Life Science News. April 2020: 36-37.
M Campbell. Consortium Members Work To Deliver UK's First COVID-19 Vaccine As Quickly and Safely As Possible. Technology Networks. April 2020. (An interview with Technical Director Tony Hitchcock)
Charlesworth J. Hitchcock T. Tharia H. Ihre H. and Hagner McWhirter Å. Purifying Plasmid DNA Using A Modern Chromatography Resin. BioProcess Online. February 2020.
P Coleman. Gene Therapy Companies’ Demands Reshape CDMOs. GEN. November 2019.
T Hitchcock. Welcoming Change. The Medicine Maker. November 2019.
Centre for Advanced Medical Products. 200 Million SEK Investment in Swedish Gene and Immunotherapy Production. October 2019.
Gidlund E. and Tuvesson O. From pill vibration to smart factories - major investments in Swedish manufacturing. Pharma Industry. June 2019.
Hitchcock T. Continuous investment – How a collaborative project aims to cut the cost of gene therapy. The Medicine Maker. February 2019.
Coleman P. Simplification of the Supply Chain Process for Advanced Therapies. Scrip100. December 2018.
Hitchcock T. and Anderson J. In The Genes - the challenges associated with manufacturing gene therapies. European Pharmaceutical Manufacturer. June 2018. (e-magazine p.25-26)
Louda B. Innovate UK Grant Supports Viral Vector Manufacturing. Contract Pharma. April 2018. (An interview with Dr Daniel Smith.)
Hitchcock T. Kaiser K. and Johnson M. Insights From Industry Experts. Disposable Solutions for Biomanufacturing Global. January 2018. (An interview with Technical Director Tony Hitchcock ahead of the Disposable Solutions conference in Amsterdam.)
Karbowniczek K. Rothwell P. Extance J. Milsom S. Lukashchuk V. Bowes K. Smith D. and Caproni L. Doggybone™ DNA: an advanced platform for AAV production. Cell & Gene Therapy Insights. November 2017.
James L. Business Awards: Cobra Biologics is investing in saving lives worldwide. The Sentinel. October 2017.
Hitchcock T. Lukashchuk V. and Bowes K. Development Approaches to Adenoassociated Virus Production. BioProcess International. September 2017.
Frazer A. and Zoro B. Process Development of Microbial Plasmid DNA: Fast-Tracking with Modular Single-Use Minibioreactors. BioProcess International. September 2017. (A follow up to our webinar in collaboration with Sartorius, available here on demand.)
Hitchcock T. Manufacturing of AAV Vectors for Gene Therapy: Building Processes for the Future. GEN. July 2017.
Björkman O. Svenska Bolagen som Deltog på Världens Största Mässa (Swedish Companies Attending the World's Largest Fair) Life Science Sweden. June 2017. Johansson J. Kontraktstillverkaren Investerar 165 Miljoner inom Genterapi (Contract Manufacturer Invests 165m in Gene Therapy) Nyteknik. May 2017.2016Lindbom Sierakowiak E. Factory in the Forest: Planning to Scale Up with Development Section. Pharma Outsourcing 2016. December 2016. (Including comments by Lars Fahlander and Peter Boman)Hitchcock T. Manufacturing Plasmid DNA: Ensuring Adequate Supplies for Gene and Cell Therapies. BioProcess International. October 2016.Cobra Expanderar på CDMO-marknaden för Biologiska Läkemedel (Cobra Expands on the CDMO-Market for Biological Drugs). Läkemedelsmarknaden. September 2016. (Interview with Magnus Gustafsson, Sales Director Cobra Biologics)Willis RC. Special Report on Stem Cells: Finding Common Ground. DDN News. August 2016. (Including comments by Dr Daniel Smith, CSO Cobra Biologics)
Smith D. Manufacturing for Chimeric Antigen Receptor (CAR) T-Cell and Gene Therapies. BioProcess International. August 2016.2015
Lindbom Sierakowick E. Levande Bakterier Ställar Nya Krav (Live Bacteria Places New Demands). Life Science Sweden. October 2015.Lopes AG, Selas Castineinas T, Hitchcock AG and Smith DC. Cost-Effective Process Development for Plasmid DNA Manufacture: Evaluation of Single-Use Technologies to Support Escherichia coli Culture. BioProcess International. October 2015.Garguilo L. 7 CEOs Say It's All About The "Bios": Biotechs, Biopharmaceuticals and Biosimilars. Outsourced Pharma. March 2015. (Interview with Peter Coleman, CEO Cobra Biologics)Halstead I. Cobra Bites Back after Tough Times. Business Quarter Magazine. Spring 2015. (Interview with Peter Coleman, CEO Cobra Biologics)Hanak J. The Rise and Rise of Cobra Biologics. UKSPA Innovation Into Success. Spring 2015: 95-98. (Link to ebook)2014
Lange I. Chhatre S. and Zoro B. Reducing Timelines in Early Process Development - Using a Multiparametric Clone-Selection and Feed-Optimization Strategy. BioProcess International. November 2014.Garguilo L. A One-Stop-Shop For Biologics Production In Europe. Outsourced Pharma. October 2014.Stanton D. Consultant: For CMO selection, its the (molecule) size that counts! BioPharma-Reporter. July 2014. (Quoted John Little, QC Manager Cobra Biologics)Lange I. Lae K. and Skoging-Nyberg U. Microbioreactors for Process Applications: Novel Approach for Cell-Line Development and Improving Decision Making at Early Stages. Genetic Engineering & Biotechnology News. February 2014. Vol 34: No 3.2013
Ellis J. Interview: Focussed and Determined. Manufacturing Chemist Pharma. December 2013: 26-27. (Interview with Peter Coleman, CEO Cobra Biologics)Hitchcock T. Viral Vaccine Manufacturing. BioPharm International. February 2013: 16-172011
Cranenburgh RM. DNA Vaccine Delivery. Biopharm International. October 2011: s12-s18.2009
Williams SG and Cranenburgh RM. Improving protein yields in mammalian cells. Genetic Engineering & Biotechnology News. June 1st 2009: 48-49.Hitchcock T. Production of recombinant whole-cell vaccines with disposable manufacturing systems. Bioprocess International. May 2009: 36-43.2008
Williams SG and Cranenburgh RM. Improving clone production for increased protein yield from mammalian cell lines. Innovations in Pharmaceutical Technology 26, 52-56, October 2008.Cranenburgh RM. Needle-Free Methods of Vaccination. BioPharm International. January 2nd, 2008.Reece-Ford M, Hitchcock AG and Lipinski K. Aspects of process development for virus vector production to improve quality and quantity. Pharmaceutical Technology Europe, January 2008.2007
Stockbridge P. Deviations and failure investigation. GMP Review, July 2007, Vol 6: 4-7.Williams SG. Increasing protein yields from transfected cells. Drug Discovery Plus International, June-July 2007: 10-12.2006
Cranenburgh RM. Antibiotic-free systems for production. Genetic Engineering News, August 2006: 61.2004
Cranenburgh RM, Bloor AE, Leckenby MW and Hanak JAJ. Engineering bacteria for DNA medicine production. European Biopharmaceutical Review, Spring 2004: 106-110.2000
Thatcher DR, Cranenburgh RM and Hanak JAJ. Innovation in DNA manufacture. Helix April 2000: 14-17.